Peregrine Pharmaceuticals reported $141.54M in Loan Capital for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Agenus AGEN:US $ 0M 12.82M
Amgen AMGN:US $ 36010M 2788M
AstraZeneca AZN:LN 28805M 83M
Biocryst Pharmaceuticals BCRX:US $ 604.46M 19M
Bristol Myers Squibb BMY:US $ 37450M 2155M
Celldex Therapeutics CLDX:US $ 0M 0M
Chemocentryx CCXI:US $ 4.55M 0.16M
Eli Lilly And LLY:US $ 15152.9M 193.5M
GlaxoSmithKline GSK:LN 29226M 8654M
Immunogen IMGN:US $ 0M 0M
Intrexon XON:US $ 201.11M 18.36M
Karyopharm Therapeutics KPTI:US $ 302.49M 198K
Macrogenics MGNX:US $ 0 0
Mannkind MNKD:US $ 375.13M 0.41M
Merk MRK:US $ 30586M 104M
Minerva Neurosciences NERV:US $ 0M 0M
Newlink Genetics NLNK:US $ 0M 0M
Novartis NOVN:VX SF 24373M 150M
Novavax NVAX:US $ 0M 323.46M
Peregrine Pharmaceuticals PPHM:US $ 141.54M 0.2M
Repligen RGEN:US $ 0M 0M
Xencor XNCR:US $ 0M 0M